InMed Pharmaceuticals is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755 CBN cream, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A. Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.
![](https://www.inmedpharma.com/wp-content/uploads/2024/08/InMed-Native-Article_Neuron-close-up-768x432.png)
Article in Fierce Biotech: The Evolving Alzheimer’s Disease Landscape
There have been major advances in Alzheimer’s disease research and development in the past two years alone. What are those breakthroughs and what’s in development